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Abstract
Pegunigalsidase alfa, a novel PEGylated, covalently crosslinked form of
α-galactosidase A developed as enzyme replacement therapy (ERT) for Fabry disease
(FD), was designed to increase plasma half-life and reduce immunogenicity, thereby
enhancing efficacy compared with available products. Symptomatic adults with FD
participated in this open-label, 3-month dose-ranging study, followed by a 9-month
extension. Three cohorts were enrolled in a stepwise manner, each receiving
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increased doses of pegunigalsidase alfa: 0.2, 1.0, 2.0 mg/kg, via intravenous infusion
every other week. Pharmacokinetic analysis occurred on Day 1 and Months 3, 6, and
12. Kidney biopsies at baseline and Month 6 assessed peritubular capillary
globotriaosylceramide (Gb3) content. Renal function, cardiac parameters, and other
clinical endpoints were assessed throughout. Treatment-emergent adverse events
(AEs) and presence of immunoglobulin G (IgG) antidrug antibodies (ADAs) were
assessed. Sixteen patients completed 1 year's treatment. Mean terminal plasma half-
life (each cohort) ranged from 53 to 121 hours. All 11 male and 1 of 7 female
patients presented with classic FD phenotype, in whom renal peritubular capillary
Gb3 inclusions were reduced by 84%. Mean estimated glomerular filtration rate was
111 mL/min/1.73 m2 at baseline, remaining stable throughout treatment. Three
patients developed treatment-induced IgG ADAs; following 1 year's treatment, all
became ADA-negative. Nearly all treatment-emergent AEs were mild or moderate.
One patient withdrew from the study following a serious related AE. Pegunigalsidase
alfa may represent an advance in ERT for FD, based on its unique pharmacokinetics
and apparent low immunogenicity.
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1 | INTRODUCTION
Fabry disease (FD) (OMIM #301500) is an X-linked genetic
disorder caused by a deficiency in the activity of the lysosomal
enzyme alpha-galactosidase A (α-Gal A) (EC 3.2.1.22),
resulting from more than 900 mutations in the GLA gene.1,2
Classically affected male patients typically have no or very
low residual enzyme activity and demonstrate accumulation of
globotriaosylceramide (Gb3) within tissues and organs, where
it is thought to contribute to serious progressive pathology in
the kidneys, cardiovascular system, and nervous system.2
Patients with residual enzyme activity, including heterozygote
females, may also develop a range of similar symptoms, typi-
cally with a later onset and a variable severity.3 Some female
patients may remain asymptomatic throughout life.
Two enzyme replacement therapies (ERTs) for FD have
been commercially available since 2003: agalsidase beta and
agalsidase alfa.4,5 The pharmacokinetic (PK) profiles of the
two drugs are similar, with half-lives of approximately
2 hours.4,5 In clinical studies of these drugs, treated patients
have demonstrated a reduction in Gb3 accumulation, improve-
ment in neuropathic pain, and trends toward improvement in
renal function and reduction in major clinical events.6–9
Pegunigalsidase alfa is a novel, PEGylated, chemically mod-
ified α-Gal A enzyme, developed as an ERT for the treatment
of FD. The enzyme is produced in a plant cell-based ProCellEx
system.10 Chemical modification with a homo-bifunctional
polyethylene glycol (PEG, 2000 Da) results in covalently
crosslinked monomers with preserved 3D structure.11 As part of
the chemical modification, additional PEG moieties are attached
to surface lysine residues by one end only. In in vitro testing,
pegunigalsidase alfa showed greater stability than agalsidase
alfa and agalsidase beta in human plasma at 37C and under
simulated lysosomal-like conditions.11 In Fabry mice, compared
with agalsidase alfa, pegunigalsidase alfa demonstrated pro-
longed plasma half-life and an enhanced biodistribution, includ-
ing increased enzymatic activity in the heart and kidney and
reduced clearance by the liver.11
This article presents the results of the 1-year treatment
experience in two Phase 1/2 clinical studies. The first study
(NCT01678898) was a 3-month dose-ranging study
followed by a 9-month extension study (NCT01769001).
These studies were designed to evaluate the pharmacokinet-
ics of pegunigalsidase alfa and assess the efficacy, safety,
and tolerability of the drug when administered to treatment-
naïve FD patients.
2 | METHODS
2.1 | Study ethics
Both study protocols were reviewed and approved by an
institutional review board or ethics committee prior to initia-
tion. All patients provided informed written consent to par-
ticipate before study enrollment. Studies were conducted in
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accordance with the ethical principles expressed in the Dec-
laration of Helsinki, approved protocol, Good Clinical Prac-
tice guidelines, and applicable regulatory requirements.
2.2 | Patients
FD symptomatic adults ≥18 years old were eligible for the
dose-ranging study. FD was confirmed in male patients by
plasma and/or leucocyte α-Gal A activity below the lower
limit of normal (plasma, <3.2 nmol/h/mL; leucocytes,
<32 nmol/h/mg protein). In females, FD was confirmed by
identification of a pathogenic variant in one of the FD GLA
genes. Additional inclusion criteria included being naive to
ERT or not having received ERT in the previous 6 months
and negative for anti-pegunigalsidase alfa IgG antibodies, and
estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73
m2. Key exclusion criteria included chronic kidney disease
stages 3 to 5 or history of renal dialysis or transplantation,
angiotensin converting enzyme (ACE) inhibitor or angioten-
sin receptor blocker (ARB) therapy dose change or initiation
within 4 weeks before screening, severe myocardial fibrosis
defined as ≥2 late-enhancement positive ventricular segments,
or a history of stroke.
2.3 | Study design
The study was an open-label, multinational, multicenter,
3-month dose-ranging study of pegunigalsidase alfa for
treatment of FD. Three cohorts of patients were enrolled in a
stepwise manner and treated with one of three increasing
dose levels of pegunigalsidase alfa: 0.2 mg/kg, 1.0 mg/kg,
or 2.0 mg/kg via intravenous infusion every other week
(EOW) (details presented in Supporting Information Appen-
dix S1). Patients completing the 3-month study were invited
to participate in the extension study, continuing to receive
their original dose for 9 additional months.
2.4 | Pegunigalsidase alfa dosing
Infusions of pegunigalsidase alfa were administered every
2 weeks (±3 days) at approved medical centers, and patients
observed for 24 hours after each of the first seven infusions
(3 months of treatment). For the 0.2- and 1.0-mg/kg cohorts,
each dose was diluted with 0.9% NaCl to a volume of
150 mL, and in the 2.0-mg/kg group to a final volume of
350 mL. The mean durations of the initial infusions in the
0.2-mg/kg, 1.0-mg/kg, and 2.0-mg/kg groups were 4.0, 5.5,
and 6.4 hours, and were sequentially reduced per protocol to
mean durations of 1.5, 3.3, and 3.1 hours at 12 months,
respectively. In the 2.0-mg/kg group, premedication con-
sisting of standard doses of H1 and H2 histamine receptor
blockers was administered at 12 hours and 2 hours prior to
the start of each infusion and was sequentially reduced
and/or discontinued as tolerated.
All procedures followed were in accordance with the eth-
ical standards of the responsible committee on human exper-
imentation (institutional and national) and with the Helsinki
Declaration of 1975, as revised in 2000 (5). Informed con-
sent was obtained from all patients for being included in the
study. Proof that informed consent was obtained is available
upon request. This article does not contain any studies with
animal subjects performed by any of the authors.
3 | ASSESSMENTS
3.1 | Pharmacokinetics
Venous blood samples for pharmacokinetic analysis were
collected into EDTA tubes on Day 1, and at 3, 6, and
12 months at the following time points: pre-infusion;
1 hour after infusion start; at the end of the infusion; at
1, 4, 8, 24, 48 ± 2, 72 ± 3, and 96 ± 3 hours; and at
2 weeks ±3 days after the end of the infusion.
Pegunigalsidase alfa concentrations were determined using
a validated enzyme-linked immunosorbent assay (ELISA)
with a lower limit of quantitation of 20 ng/mL in plasma.
The following noncompartmental pharmacokinetic parame-
ters were derived from the plasma concentration-time cur-
ves using Phoenix WinNonlin 6.3 (Certara, L.P.,
Princeton, New Jersey): maximum observed concentration
(Cmax), terminal half-life (T1/2γ), area under the plasma
concentration-time curve from 0 hours to infinity
(AUC0-∞), volume of distribution during the elimination
phase (Vz), and plasma clearance (Cl).
3.2 | Pharmacodynamics
Kidney biopsies obtained at baseline and after 6 months of
treatment were fixed in glutaraldehyde and embedded in resin.
Semithin sections were obtained and stained with toluidine
blue, and glass slides were scanned into whole slide images
(at 100x). Three hundred cortical peritubular capillaries per
case were digitally annotated and blindly assessed by three
renal pathologists for Gb3 inclusion using the quantitative Bar-
isoni Lipid Inclusion Scoring System (BLISS).12
Plasma Gb3 and lyso-Gb3 concentrations were assayed in
venous blood obtained before dosing initiation, at each study
visit in the first 3 months, and every 3 months thereafter.
Plasma lyso-Gb3 was extracted and quantified according to
Boutin and colleagues,13 with minor modifications: dimethyl
psychosine was used as an internal standard in place of N-gly-
cinated lyso-ceramide. Plasma Gb3 was extracted and quanti-
fied according to Mills and colleagues.14
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3.3 | Clinical effect
The estimated glomerular filtration rate (eGFR) was calculated
using the Chronic Kidney Disease-Epidemiology Collabora-
tion (CKD-EPI) equation.15 Proteinuria was determined from
a spot urine sample and expressed as the ratio of urine protein
to creatinine excretion (UPCR; mg/g). These renal variables
were assessed at every visit during the first 3 months and
every 3 months thereafter. Cardiac MRI was performed at
baseline and after 6 and 12 months of treatment to estimate
left ventricular mass (LVM), LVM index (LVMi), and ejec-
tion fraction (EF), and to assess the presence of cardiac fibro-
sis. Pain was assessed using the Brief Pain Inventory (BPI;
Short Form) at baseline and after every 3 months of treatment.
The Mainz Severity Score Index (MSSI) was used to assess
the overall burden of FD symptoms at baseline and after every
6 months of treatment.16 Effect of treatment on severity and
frequency of abdominal pain and frequency of diarrhea was
assessed using a questionnaire described by Dehout et al17
given to patients at baseline and every 3 months thereafter.
3.4 | Safety
Treatment-emergent adverse events (TEAEs), clinical labo-
ratory measurements, physical examinations, and electrocar-
diographic findings were assessed during the study. The
presence and titers of anti-pegunigalsidase alfa immunoglob-
ulin G (IgG) antibodies were determined by a validated
direct ELISA. Antidrug antibody (ADA)-positive samples
were further characterized, including their neutralizing activity,
using an enzymatic activity assay. These assays were devel-
oped and validated based on the current immunogenicity
guidelines from the United States Food and Drug Administra-
tion and European Medicines Agency.
3.5 | Analysis
Because of the small number of patients at each dose level
and the study design, only descriptive statistics are presented
as mean ± SD unless otherwise stated. The results are sum-
marized for the following groups of patients: all patients and
patients with a classic phenotype presentation of FD. Classic
phenotype FD was defined as patients with low (<30% of
the normal laboratory mean) values of α-Gal A activity and
at least one FD-specific symptom, such as neuropathic pain,
cornea verticillata, or clustered angiokeratoma.
4 | RESULTS
4.1 | Patients
Forty-two patients from 13 sites were screened for eligibil-
ity, with 19 patients from 11 sites enrolled. Of the
23 screening failures, 9 had α-Gal A activity inconsistent
with FD and 14 failed to meet other inclusion criteria. One
patient designated for the 1.0-mg/kg group voluntarily with-
drew from the study before receiving study treatment. Thus,
the safety population comprised 18 patients receiving any
dose of study drug. Two male patients in the 1.0-mg/kg
treatment group discontinued the study: one experienced a
hypersensitivity reaction (bronchospasm) during the first
infusion, and one was noncompliant. All 11 male patients
and a single female patient were classified as having classic
phenotype FD. Of the 16 treated patients who completed the
study, four were treated with an ACE inhibitor or ARB at
baseline. Of the 16 patients who completed 12 months of
treatment, 15 enrolled in an extension study
(NCT01981720). Baseline characteristics are presented in
Table 1 (patient disposition and summary baseline character-
istics of the safety population are presented in Supporting
Information Appendix S1, figure 1 and table
1, respectively).
4.2 | Pharmacokinetics
Measurable concentrations of pegunigalsidase alfa were pre-
sent throughout the entire 14-day dosing interval (Figure 1).
Calculated pharmacokinetic parameters (Supporting Infor-
mation Appendix S1, table 2) Cmax and AUC0-∞ demon-
strated dose-related increases on each sampling day. T1/2γ,
Cl, and Vz did not systematically change with increasing
dose within each sampling day but did exhibit variability
among the three doses. The mean AUC0−∞ increased
between Day 1 and 3 months for all dose levels. Subsequent
increases in AUC0-∞ with increasing treatment duration
were observed for the 1.0- and 2.0-mg/kg dose levels, but
not at 0.2 mg/kg. Overall mean T1/2γ was about 80 hours
and ranged from 53 to 121 hours.
4.3 | Pharmacodynamics
Kidney biopsies from three patients were excluded from this
analysis: one from a male not handled according to protocol,
one from a female with no cortical tissue, and one from a
male patient that revealed minimal tissue involvement (base-
line BLISS score of 0.44). In the remaining 13 patients ana-
lyzed, a mean decrease in peritubular capillary Gb3 content
of 67.8% ± 8.9% was observed after 6 months, and in the
eight patients with classic phenotype FD who were ana-
lyzed, a mean decrease of 84.1% ± 3.3% was found
(Figure 2). At the 6-month time point, 11 of the 13 patients
demonstrated more than 50% reduction in the number of
Gb3 inclusions.
Reductions in plasma Gb3 and lyso-Gb3 levels were
observed throughout the study in the entire population
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including patients with classic phenotype FD (details pres-
ented in Supporting Information Appendix S1, Results; fig-
ure 2).
4.4 | Clinical effect
At baseline, mean eGFR was 111.2 ± 20.9 mL/min/1.73 m2
(range: 78-156 mL/min/1.73 m2). In the entire study popula-
tion, minimal change in mean eGFR of −0.8 ±
7.7 mL/min/1.73 m2 was observed over the 12 months of
treatment (12-month mean: 110.5 ± 23.4 mL/min/1.73 m2;
range: 68-152 mL/min/1.73 m2). In the 10 patients with
classic phenotype FD, the mean annualized eGFR slope (cal-
culated from monthly measurement, total of 6-7 data points
per patient) was −1.8 mL/min/1.73 m2/year (range:
−18.18-6.35 mL/min/1.73 m2/year). Upon excluding one
male patient who was treated with doxycycline, which may
transiently exacerbate renal disease,18 the remaining group
of nine classic patients demonstrated a mean eGFR slope of
0.01 mL/min/1.73 m2/year (range: −6.35-6.35 mL/min/1.73
m2/year) (Supporting Information Appendix S1, figure 3).
At baseline, 12 patients had normal UPCR and four had
UPCR above normal (<200 mg/g). After 12 months,
14 patients had normal UPCR levels (baseline and final
UPCR measurements are presented in Supporting Informa-
tion Appendix S1, table 3). Two additional patients with the
highest baseline UPCR demonstrated a decrease during
treatment (a female patient improved from 405 to 240 mg/g,
and a male patient improved from 298 mg/g to 209 mg/g).
No patient initiated or increased the dose of an ACE inhibi-
tor or ARB during treatment.
Other exploratory clinical outcomes are presented in
detail in the Supporting Information Appendix S1. Briefly,
at baseline, mean LVM and LVMi were within the normal
range, and no cardiac fibrosis was present. Cardiac MRI
results showed that the majority of patients maintained car-
diac parameters (LVM, LVMi, and EF) within the normal
ranges throughout the 12-month study, with a slight decrease
in LVMi in patients with classic phenotype FD. No new
fibrosis was observed. Improvements in BPI pain scores and
in each subscale of the MSSI were observed during the
study. A favorable trend was seen in gastrointestinal symp-
toms over 12 months.
4.5 | Safety
A total of 223 TEAEs were reported in 17 of the 18 treated
patients, and 169 (75.8%) were deemed to be not related or
unlikely to be related to treatment. All TEAEs were of mild
or moderate intensity, with the exception of four patients
who each experienced a TEAE that was considered severe,
including pain in extremity, renal hematoma due to kidney
biopsy at baseline, migraine, and bronchospasm. Of these
four events, migraine and bronchospasm were considered
possibly related and definitely related to treatment, respec-
tively. The bronchospasm event occurred 40 minutes after
starting the first infusion of pegunigalsidase alfa, was treated
with epinephrine and corticosteroids, and resolved without
sequelae. The patient was withdrawn from the study per pro-
tocol, and this event was reported as a related serious
adverse event (AE). This patient had pre-existing IgE anti-
pegunigalsidase antibodies.
The most common TEAEs in the safety population were
fatigue (n = 6 patients; 33%), nausea (n = 5; 28%), and
vomiting (n = 5; 28%). The most common TEAEs consid-
ered possibly related to treatment were nausea (n = 4; 25%)
and chest discomfort, dizziness, maculopapular rash, and
fatigue (n = 2 patients each; 13%). Eight patients (including
FIGURE 1 Pegunigalsidase alfa plasma levels following dosing
on Day 1. SD, standard deviation
FIGURE 2 Reduction of Gb3 deposition in kidney peritubular
capillaries following 6 months of pegunigalsidase alfa treatment. BL,
baseline; BLISS, Barisoni Lipid Inclusion Scoring System; Gb3,
globotriaosylceramide; SD, standard deviation. The three dosing
groups were combined for this analysis
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the patient with bronchospasm) experienced a total of
30 TEAEs that occurred during or within 2 hours after infu-
sion of pegunigalsidase alfa (Table 2); 24 of these TEAEs
were deemed to be probably, possibly, or definitely related
to treatment. The majority of laboratory hematology, bio-
chemistry, and urinalysis parameters remained within nor-
mal levels, and no clinically important mean changes from
baseline were observed.
4.5.1 | Antibodies
Three patients, all male, developed treatment-induced IgG
ADAs following treatment with pegunigalsidase alfa: two
patients in the 0.2-mg/kg group (maximum titers 2198 and
4633) and one in the 1.0-mg/kg group (maximum titer 237).
No patient in the 2.0-mg/kg group developed treatment-
induced ADAs. All three patients became ADA-negative
after approximately 1 year of treatment, suggesting immune
tolerance induction. The ADAs in the two patients in the
0.2-mg/kg group were transiently neutralizing but became
non-neutralizing as treatment continued, with transient and
reversible effects on pharmacokinetics (i.e., an increase in
enzyme clearance and a decrease in T1/2γ; Figure 3). No
influence of ADAs on pharmacodynamics, efficacy, or
safety responses was evident.
5 | DISCUSSION
ERT for the treatment of FD has been available since the
early 2000s. However, beneficial clinical responses have not
been consistently reported and have not been as robust as
initially anticipated.2,19–21 Here, we report that treatment
with pegunigalsidase alfa in FD patients results in an
extended drug plasma coverage and low immunogenicity
that distinguish this novel ERT from the two commercially
available products. Furthermore, we report the specific
effects of the presence of ADAs on drug PK, which, to our
knowledge, is the first report of its kind.
Compared with previous pharmacokinetic reports for
agalsidase alfa and beta, both of which exhibit a T1/2γ of
≤2 hours and maintain measurable plasma levels for
<24 hours,4,5 pegunigalsidase alfa had a T1/2γ of about
80 hours, with measurable plasma levels sustained for the
entire 2-week dosing interval, thus providing an active
enzyme reservoir in the circulation to reach the target tis-
sues. The covalent crosslinking, keeping the protein in its
TABLE 2 Adverse events occurring during or within 2 hours of completion of an infusion of pegunigalsidase alfa
Dose (mg/kg) Subject Visit Adverse events (CRF term/MedDRA preferred term) Treatment relationship
0.2 1 1 Headaches/Headache Unrelated
3 3 Generalized itching/Pruritus generalized Unlikely




27 Sneezing and sinus drainage/Paranasal sinus hypersecretion Possibly
1.0 7 2, 15 Hypotension/Hypotension Probably
3 Lightheadedness/Dizziness Possibly
9 Shortness of breath/Dyspnea Possibly
13 Maculo-papular erythematous/Rash maculo-papular Probably
8 6, 8 Infusion reaction/Infusion related reaction Possibly
15 Pain at left chest/Chest pain Possibly
17 Itching/Pruritus Possibly
17 Rash/Rash Unlikely
18 Rash at tape site/Dermatitis contact Unrelated
20 Nausea/Nausea Possibly
20 Dizziness/Dizziness Possibly
11 1 Bronchospasm/Bronchospasm Definitely
2.0 17 1-7 Abdominal cramping/Abdominal pain Possibly
18 3 Epigastric pain/Abdominal pain upper Unrelated
Abbreviations: CRF, case report form; MedDRA, Medical Dictionary for Regulatory Activities.
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homodimer-active configuration and maintaining stable enzy-
matic activity, combined with additional PEG moieties
attached to the protein surface, contribute to the prolonged
plasma half-life and subsequent delivery to target tissues11 and
may mask epitopes responsible for generating an immune
response.22 Preliminary in vitro experiments demonstrated less
recognition of pegunigalsidase alfa compared to agalsidase
alfa or beta.23 Immunogenicity is an important concept in the
use of ERT in FD. In clinical trials, 68% and 73%6,24 of adults
(both sexes and males, respectively) treated with agalsidase
beta and 24% to 56% of male adults treated with agalsidase
alfa developed ADAs,5,25 with a high incidence of neutralizing
antibodies.26 The presence of neutralizing ADAs has been
associated with reduced pharmacodynamic and clinical
responses,25,26 such as severely impaired cardiac structural
disease burden and renal outcome, increasing lyso-Gb3 levels,
and worse severity score values.26
In the present study, three patients (19%) treated with
pegunigalsidase alfa developed treatment-induced ADAs,
two of which had neutralizing activity. In all cases, the ADA
response was transient, with no observed impact on pharma-
codynamics, efficacy, or safety. Importantly, no patients
treated with the highest dose, 2.0 mg/kg, were ADA-positive
at any time.
The pharmacodynamic data demonstrating substantial
decrease in Gb3 deposition in kidney peritubular capillaries
and a decrease in plasma lyso-Gb3 are predictors of possible
clinical benefit of pegunigalsidase alfa in Fabry disease
patients.
Progressive deterioration of kidney function is one of the
major contributors to morbidity and mortality in classically
affected patients with FD.2,27 Current experience in FD sug-
gests that continuous ERT may slow the progression of
chronic kidney disease; however, a subset of treated patients
FIGURE 3 The effect of ADA positivity on pharmacokinetics and pharmacodynamics of pegunigalsidase alfa. (A) IgG ADA titer, with red
symbols indicating neutralizing antibodies. (B) Pharmacokinetic profiles on Day 1 and at Months 3, 6, and 12. (C) Lyso-Gb3 levels. ADA, antidrug
antibody; IgG, immunoglobulin G; lyso-Gb3, lyso-globotriaosylceramide. The IgG titers in these three patients have now been followed for at least
24 months and have remained at 0
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is characterized by excessive proteinuria (≥1 g/day) or low
baseline GFR (<60 mL/min/1.73 m2) and, as a result, are at
high risk for continued loss of renal function.9,27–29 In the
present study with ERT-naïve patients, eGFR was stable
during the 1-year treatment period. This observation, com-
bined with the reduction in proteinuria in a small number of
patients with baseline UPCR ≥200 mg/g, suggests that
pegunigalsidase alfa may stabilize renal function. However,
it should be noted that given their normal baseline eGFR
and low proteinuria levels, this cohort was already at low
risk for loss of eGFR over the study period.
Cardiac manifestations of FD, including left ventricular
hypertrophy, myocardial fibrosis, and associated functional
deterioration, also contribute to the morbidity and mortality
of the disease.30,31 In this study, a small decrease in LVMi
was observed in patients with classic phenotype FD during
the 1-year treatment period, although it is important to note
that with no fibrosis and normal LVMi prior to treatment in
these low-risk patients, no significant improvement would
have been expected. Other exploratory clinical outcomes
also showed beneficial trends, suggesting the clinical value
of pegunigalsidase alfa.
Repeated administration of pegunigalsidase alfa in ERT-
naïve male and female patients with FD was well tolerated,
and no safety issues unique to this novel ERT for the treat-
ment of FD were observed. Infusion reactions have been
reported in ~50% of patients treated with agalsidase beta,
necessitating use of antipyretic and antihistaminic
premedication.4 In this study, 24 possible infusion reactions
(defined as possibly, probably, or definitely TEAEs occur-
ring during or within 2 hours post-infusion) occurred out of
the total of 223 TEAEs. One patient experienced a hypersen-
sitivity reaction (bronchospasm) during the first infusion and
was withdrawn from the study per protocol. Premedication
was used only in the 2.0-mg/kg group and is being discon-
tinued during the extension study.
6 | STUDY LIMITATIONS
This open-label dose-ranging study was limited by the small
number of patients in each dose group, the lack of a control
group, and the cohort's relatively mild FD, resulting in lim-
ited potential for disease progression.
7 | CONCLUSIONS
The unique pharmacokinetics and the apparent attenuated
immune response demonstrated by pegunigalsidase alfa may
improve the safety and clinical response to this ERT in
patients with FD. This is supported by the favorable AE pro-
file, stability of renal function and cardiac parameters, and
improved disease symptoms observed in the study partici-
pants during the 12-month treatment period. The clinical
efficacy of pegunigalsidase alfa is being further evaluated in
three Phase 3 clinical studies.
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